Literature DB >> 26896670

Histories of abuse predict stronger within-person covariation of ovarian steroids and mood symptoms in women with menstrually related mood disorder.

Tory A Eisenlohr-Moul1, David R Rubinow2, Crystal E Schiller3, Jacqueline L Johnson4, Jane Leserman5, Susan S Girdler6.   

Abstract

OBJECTIVE: Individual differences in sensitivity to cyclical changes in ovarian steroids estradiol (E2) and progesterone (P4) have been implicated in the pathophysiology of menstrually related mood disorder (MRMD). However, no prospective studies have investigated psychosocial risk factors for sensitivity to hormone effects on mood in MRMD. Using a repeated measures approach and multilevel models, we tested the hypothesis that a history of abuse provides a context in which within-person elevations of E2 and P4 prospectively predict daily symptoms.
METHOD: 66 women with prospectively-confirmed MRMD recruited for a trial of oral contraceptives provided 1 month of baseline hormone and mood data prior to randomization. Lifetime physical and sexual abuse experiences were assessed. Across one cycle, women completed daily measures of symptoms and provided blood samples on 5 days across the menstrual cycle. Current E2 and P4 were centered within person (CWP) such that higher values represented cyclical elevations in hormones.
RESULTS: Rates of physical (27%) and sexual (29%) abuse were high, consistent with previous work documenting a link between trauma and MRMD. In women with a history of physical abuse, cyclical increases in P4 predicted greater mood and interpersonal symptoms on the three days following that sample. In women with a history of sexual abuse, cyclical increases in E2 predicted greater anxiety symptoms on the three days following that sample.
CONCLUSIONS: Results inform further inquiry into the role of severe life stressors and stress response systems in MRMD. We discuss areas for future research on the psychosocial and physiological pathways through which abuse may influence the link between hormones and symptoms.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Abuse; Estradiol; Ovarian steroid hormones; Premenstrual dysphoric disorder; Progesterone

Mesh:

Substances:

Year:  2016        PMID: 26896670      PMCID: PMC4811338          DOI: 10.1016/j.psyneuen.2016.01.026

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  44 in total

1.  Ovarian hormones and borderline personality disorder features: Preliminary evidence for interactive effects of estradiol and progesterone.

Authors:  Tory A Eisenlohr-Moul; C Nathan DeWall; Susan S Girdler; Suzanne C Segerstrom
Journal:  Biol Psychol       Date:  2015-03-30       Impact factor: 3.251

2.  The effects of gonadal steroids on brain stimulation reward in female rats.

Authors:  E P Bless; K A McGinnis; A L Mitchell; A Hartwell; J B Mitchell
Journal:  Behav Brain Res       Date:  1997-01       Impact factor: 3.332

3.  Steroid hormone metabolites potentiate GABA receptor-mediated chloride ion flux with nanomolar potency.

Authors:  A L Morrow; P D Suzdak; S M Paul
Journal:  Eur J Pharmacol       Date:  1987-10-27       Impact factor: 4.432

4.  Daily plasma estradiol and progesterone levels over the menstrual cycle and their relation to premenstrual symptoms.

Authors:  E Redei; E W Freeman
Journal:  Psychoneuroendocrinology       Date:  1995       Impact factor: 4.905

5.  Evidence of direct estrogenic regulation of human corticotropin-releasing hormone gene expression. Potential implications for the sexual dimophism of the stress response and immune/inflammatory reaction.

Authors:  N C Vamvakopoulos; G P Chrousos
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

6.  Gonadal steroids exert facilitating and "buffering" effects on glucocorticoid-mediated transcriptional regulation of corticotropin-releasing hormone and corticosteroid receptor genes in rat brain.

Authors:  V K Patchev; O F Almeida
Journal:  J Neurosci       Date:  1996-11-01       Impact factor: 6.167

7.  Hypothalamic-pituitary-thyroid axis function in women with a menstrually related mood disorder: association with histories of sexual abuse.

Authors:  Adomas Bunevicius; Jane Leserman; Susan S Girdler
Journal:  Psychosom Med       Date:  2012-09-21       Impact factor: 4.312

8.  Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial.

Authors:  C S Brown; F W Ling; R N Andersen; R G Farmer; K L Arheart
Journal:  Obstet Gynecol       Date:  1994-11       Impact factor: 7.661

9.  The neurosteroid tetrahydroprogesterone counteracts corticotropin-releasing hormone-induced anxiety and alters the release and gene expression of corticotropin-releasing hormone in the rat hypothalamus.

Authors:  V K Patchev; M Shoaib; F Holsboer; O F Almeida
Journal:  Neuroscience       Date:  1994-09       Impact factor: 3.590

10.  Intrahypothalamic estradiol modulates hypothalamus-pituitary-adrenal-axis activity in female rats.

Authors:  J Liu; P H Bisschop; L Eggels; E Foppen; E Fliers; J N Zhou; A Kalsbeek
Journal:  Endocrinology       Date:  2012-05-04       Impact factor: 4.736

View more
  17 in total

Review 1.  Stress, sex hormones, inflammation, and major depressive disorder: Extending Social Signal Transduction Theory of Depression to account for sex differences in mood disorders.

Authors:  George M Slavich; Julia Sacher
Journal:  Psychopharmacology (Berl)       Date:  2019-07-29       Impact factor: 4.530

Review 2.  Progesterone, reproduction, and psychiatric illness.

Authors:  Lindsay R Standeven; Katherine O McEvoy; Lauren M Osborne
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2020-06-18       Impact factor: 5.237

3.  Efficacy of Transdermal Estradiol and Micronized Progesterone in the Prevention of Depressive Symptoms in the Menopause Transition: A Randomized Clinical Trial.

Authors:  Jennifer L Gordon; David R Rubinow; Tory A Eisenlohr-Moul; Kai Xia; Peter J Schmidt; Susan S Girdler
Journal:  JAMA Psychiatry       Date:  2018-02-01       Impact factor: 21.596

4.  Trauma Characteristics Moderate the Relation Between Estradiol and Trauma-Related Symptoms.

Authors:  Jenna K Rieder; Olena Kleshchova; Mariann R Weierich
Journal:  J Trauma Stress       Date:  2021-08-13

5.  Toward the Reliable Diagnosis of DSM-5 Premenstrual Dysphoric Disorder: The Carolina Premenstrual Assessment Scoring System (C-PASS).

Authors:  Tory A Eisenlohr-Moul; Susan S Girdler; Katja M Schmalenberger; Danyelle N Dawson; Pallavi Surana; Jacqueline L Johnson; David R Rubinow
Journal:  Am J Psychiatry       Date:  2016-08-13       Impact factor: 18.112

6.  Evolution, the Menstrual Cycle, and Theoretical Overreach.

Authors:  Jeff Kiesner; Tory Eisenlohr-Moul; Jane Mendle
Journal:  Perspect Psychol Sci       Date:  2020-06-15

Review 7.  Suicide Risk and the Menstrual Cycle: a Review of Candidate RDoC Mechanisms.

Authors:  Sarah A Owens; Tory Eisenlohr-Moul
Journal:  Curr Psychiatry Rep       Date:  2018-10-06       Impact factor: 5.285

8.  Understanding When and Why Some Adolescent Girls Attempt Suicide: An Emerging Framework Integrating Menstrual Cycle Fluctuations in Risk.

Authors:  Sarah A Owens; Tory A Eisenlohr-Moul; Mitchell J Prinstein
Journal:  Child Dev Perspect       Date:  2020-05-07

Review 9.  Ovarian Hormones as a Source of Fluctuating Biological Vulnerability in Borderline Personality Disorder.

Authors:  Jessica R Peters; Tory A Eisenlohr-Moul
Journal:  Curr Psychiatry Rep       Date:  2019-10-17       Impact factor: 5.285

Review 10.  How to study the menstrual cycle: Practical tools and recommendations.

Authors:  Katja M Schmalenberger; Hafsah A Tauseef; Jordan C Barone; Sarah A Owens; Lynne Lieberman; Marc N Jarczok; Susan S Girdler; Jeff Kiesner; Beate Ditzen; Tory A Eisenlohr-Moul
Journal:  Psychoneuroendocrinology       Date:  2020-10-13       Impact factor: 4.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.